That was 2019 …
The year is coming to an end. Also in 2019, there were many interesting news for MS patients, which I also partly commented on in this blog. In my opinion, nothing really groundbreaking has happened.
Continue reading
Year: 2019
Approval Change of Interferon-beta Therapy during Pregnancy and Lactation
In late September 2019, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended a change in the authorization of Interferon-beta therapy during pregnancy and lactation. Although this is actually very
Continue reading
The New S1P Modulators
In addition to the study data from Ofatumumab, which I had already reported on (see DocBlog post from September 2019), another new study program was presented at ECTRIMS 2019 in Stockholm. It is the so-called
Continue reading
Approval of Siponimod in the USA and Europe – the vote of the regulatory authorities
The new MS drug Siponimod, the further development of Fingolimod (Gilenya®), was recently approved by the Food and Drug Administration (FDA) in the USA and has been available there for some time for MS patients
Continue reading
Flu Vaccination!
It is now again the time to get vaccinated against the flu – hence this post as a reminder: The flu vaccination is neither dangerous for MS patients nor does it trigger flare-ups. On the
Continue reading
Autologous Hematopoietic Stem Cell Transplantation (HSCT)
I have touched on this topic several times in the past in congress reports – in view of a currently increasing demand, I would like to go into more detail on HSCT (= engl. Hematopoietic
Continue reading
News from the DGN Congress 2019
From September 25th to 28th, the 92nd Congress of the German Society for Neurology took place in Stuttgart. The congress covers the entire spectrum of scientific and clinical neurology, but of course MS – as
Continue reading
Immunotherapy is not everything…
Immunotherapy for MS is an important measure for many patients, but it is not the only strategy we use. Although immunotherapies are particularly important therapeutic measures in the early stages of the disease, this (apparent)
Continue reading
News from ECTRIMS – Ofatumumab
Last week, the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place in Stockholm. ECTRIMS is the world’s largest and most significant conference on Multiple Sclerosis – therefore,
Continue reading
Medication Therapy – Pragmatism is Required
“I don’t like to take medication” – I hear this sentence very often. Believe it or not, I have absolute understanding for this attitude. Because it is certainly most pleasant when you don’t constantly have
Continue reading
